187 related articles for article (PubMed ID: 14557967)
1. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
[TBL] [Abstract][Full Text] [Related]
2. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
3. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
4. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
6. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
7. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
8. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
9. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
10. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
11. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
13. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
14. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
16. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children.
Resino S; Bellon JM; Resino R; Navarro ML; Tomás Ramos J; de José MI; Mellado MJ; Muñoz-Fernández MA
Clin Infect Dis; 2004 Jun; 38(11):1605-12. PubMed ID: 15156450
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
Stone SF; Price P; French MA
HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
[TBL] [Abstract][Full Text] [Related]
20. Changes in viral load in people with virological failure who remain on the same HAART regimen.
Cozzi-Lepri A; Phillips AN; Miller V; Katlama C; Ledergerber B; Vella S; Weber J; Bruun JN; Kirk O; Clotet B; Lundgrens JD
Antivir Ther; 2003 Apr; 8(2):127-36. PubMed ID: 12741625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
